ClearNote Health is a cancer detection company focused on enabling people at risk for high-mortality cancers to live longer, healthier lives. Our first product, the Avantect Pancreatic Cancer Test, is a test for patients at high risk for pancreatic cancer, including those newly diagnosed with type 2 diabetes age 50+.
Pancreatic cancer is a devastating disease, most frequently diagnosed too late. The Avantect Pancreatic Cancer Test is a simple cell-free DNA-based blood test designed to help make earlier diagnosis possible, and to offer an improved chance for successful treatment and longer survival.
Stop by our Booth #1814 at the American Diabetes Association’s 83rd Scientific Sessions in San Diego, June 23-26, to learn more about the test and how it can easily be incorporated into clinical management protocols for high-risk patients. A simple blood draw can deliver life-changing information.
Please get in touch with us directly if you would like to ask us any questions in advance of the conference. We look forward to talking with you!
To learn more about the Avantect Pancreatic Cancer Test, visit avantect.com.
About ClearNote Health
ClearNote Health is a cancer detection company focused on enabling people at risk for high-mortality cancers to live longer healthier lives. Utilizing a standard blood draw, the company applies its proprietary epigenomic platform, combining biology and artificial intelligence, to identify DNA-based changes in biology as cancer develops. With lead programs in non-invasive early detection of pancreatic and ovarian cancers in patients at the highest risk for these diseases, ClearNote Health identifies cancers before they progress and when patients are most likely to benefit from treatment. ClearNote Health is headquartered in San Diego, with additional presence in the San Francisco Bay area and internationally. The company’s CLIA- and CAP-accredited laboratory is located in San Diego, Calif.
